Prothena (PRTA)
(Real Time Quote from BATS)
$20.00 USD
+0.22 (1.11%)
Updated Aug 6, 2024 12:08 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
PRTA 20.00 +0.22(1.11%)
Will PRTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRTA
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Prothena (PRTA) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
Other News for PRTA
Commit To Purchase Prothena At $17.50, Earn 34.3% Annualized Using Options
Prothena to Report Second Quarter 2024 Financial Results on August 8
Prothena (PRTA) Receives a Hold from RBC Capital
Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships